BackAyala Pharmaceuticals Overview

Ayala Pharmaceuticals Long Term Debt

Track Ayala Pharmaceuticals's long-term debt ($1.8M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$1.75M

Peer average

Loading

Ayala Pharmaceuticals Long Term Debt History

Loading

Ayala Pharmaceuticals vs. peers: Long Term Debt Comparison

Loading

Ayala Pharmaceuticals Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Ayala Pharmaceuticals (AYLA) FAQ

Ayala Pharmaceuticals (AYLA) currently reports a long-term debt of $1.8M as of December 2022. In the prior-year period, the figure was $0. Use the charts on this page to explore Ayala Pharmaceuticals's long-term debt history and peer comparisons.

Ayala Pharmaceuticals's long-term debt changed from $0 to $1.8M (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Ayala Pharmaceuticals reported $1.8M in long-term debt as of December 2022. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $1.8M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Ayala Pharmaceuticals, and consider following AYLA for alerts when major investors trade the stock.

Ayala Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $1.8M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AYLA with unrelated industries.